Bart Fevery
Impact in
- Hepatology top 0.5%
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
Papers in
- Hepatology 26
- Hepatitis C virus research 26
-
- Immunotherapy and Immune Responses 2
- Immune Response and Inflammation 2
- Immunotoxicology and immune responses 1
- Co-authors
- Oliver Lenz (18 shared papers)Monika Peeters (7 shared papers)Gastón Picchio (9 shared papers)Leen Vijgen (7 shared papers)James Witek (5 shared papers)Sandra De Meyer (9 shared papers)Thierry Verbinnen (6 shared papers)Ronald Kalmeijer (5 shared papers)
- Journals
- Journal of Hepatology (12 papers)Hepatology (3 papers)Antiviral Therapy (2 papers)The Lancet (1 paper)Antiviral Research (1 paper)
- Partner nations
- BelgiumUnited StatesGermany
In The Last Decade
Bart Fevery
29 papers receiving 1.5k citations
Bart Fevery's Hit Papers
Peers
Comparison fields: 5 of 43
- Hepatology 1.5k
- Epidemiology 44
- Infectious Diseases 20
- Economics and Econometrics 27
- Family Practice 2
Countries citing papers authored by Bart Fevery
This map shows the geographic impact of Bart Fevery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Fevery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Fevery more than expected).
Fields of papers citing papers by Bart Fevery
This network shows the impact of papers produced by Bart Fevery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Fevery. The network helps show where Bart Fevery may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart Fevery, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Hit paper breakdown → | 2014 | 659 |
| 2 | 2015 | 167 | |
| 3 | 2016 | 166 | |
| 4 | 2014 | 121 | |
| 5 | 2015 | 91 | |
| 6 | 2012 | 78 | |
| 7 | 2015 | 71 | |
| 8 | 2013 | 30 | |
| 9 | 2016 | 28 | |
| 10 | 2014 | 25 | |
| 11 | 2012 | 21 | |
| 12 | 2010 | 20 | |
| 13 | 2015 | 20 | |
| 14 | 2013 | 16 | |
| 15 | 2019 | 9 | |
| 16 | 2015 | 8 | |
| 17 | 2021 | 7 | |
| 18 | 2016 | 6 | |
| 19 | 2018 | 6 | |
| 20 | 2019 | 6 |
About Bart Fevery
Bart Fevery is a scholar working on Hepatology, Immunology, Epidemiology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 30 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatitis C virus research (26 papers), Immunotherapy and Immune Responses (2 papers), Immune Response and Inflammation (2 papers), Hepatitis B Virus Studies (2 papers) and Immunotoxicology and immune responses (1 paper). The work is most often cited by research in Hepatology (1.5k citations), Epidemiology (44 citations), Infectious Diseases (20 citations), Economics and Econometrics (27 citations) and Family Practice (2 citations). Bart Fevery has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Oliver Lenz, Monika Peeters, Gastón Picchio, Leen Vijgen, James Witek, Sandra De Meyer, Thierry Verbinnen, Ronald Kalmeijer, Guy De La Rosa and Annemie Buelens. Their work appears in journals such as Journal of Hepatology, Hepatology, Antiviral Therapy, The Lancet and Antiviral Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.